Meritage Portfolio Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Meritage Portfolio Management’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-29,397	Closed	-$22.2M	–	338
2021 Q4	$22.2M	Sell	29,397 -412	-1%	-$308K	1.26%	16
2021 Q3	$22.2M	Buy	29,809 +34	+0.1%	+$25.5K	1.33%	13
2021 Q2	$19.2M	Sell	29,775 -311	-1%	-$189K	1.16%	17
2021 Q1	$17.2M	Sell	30,086 -1,231	-4%	-$729K	1.15%	19
2020 Q4	$18.3M	Buy	31,317 +133	+0.4%	+$75.7K	1.34%	16
2020 Q3	$16.1M	Sell	31,184 -104	-0.3%	-$52.7K	1.44%	15
2020 Q2	$14.1M	Buy	31,288 +1,204	+4%	+$531K	1.36%	19
2020 Q1	$10.5M	Buy	+30,084	New	+$11.1M	1.43%	17

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Meritage Portfolio Management's BIO Position: Q1 2022 in Review

Meritage Portfolio Management sold out of Bio-Rad Laboratories Class A (BIO) in Q1 2022, closing a stake of 29,397 shares — an estimated $22.2M sold.

Meritage Portfolio Management first reported a position in BIO in Q1 2020 and held it in 8 quarters. The position peaked at $22.2M in Q3 2021. 514 funds tracked by Wall St. Rank hold BIO as of Q1 2022.

Meritage Portfolio Management reported no remaining Bio-Rad Laboratories Class A position as of Q1 2022 after selling out during the quarter.
Meritage Portfolio Management sold 29,397 Bio-Rad Laboratories Class A shares in Q1 2022, an estimated $22.2M.
Meritage Portfolio Management first reported a position in Bio-Rad Laboratories Class A in Q1 2020 and held it in 8 quarters.
Meritage Portfolio Management's Bio-Rad Laboratories Class A position peaked at $22.2M in Q3 2021.
514 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2022.

Based on Meritage Portfolio Management's 13F filing for Q1 2022, filed 25 Apr 2022.